Promises of eukaryotic ribonucleases for cancer treatment: a systematic review

Table 4 Percent cell viability of RNase treated and untreated cell lines

S/N	Author, YYYY	RNase	Experiment		Viable cells (%)* (primary inoculation of < 5.5 × 10⁵ cells/well)				Overall cell viability
S/N	Author, YYYY	RNase	Cell lines (Description)	Concentration	0 h	24 h	48 h	72 h	Overall cell viability
1	Laccetti et al., 1994 [12]	BS-RNase	3LL (Murine Lewis lung metastasis cells)	Control	100	100	100		↓↓↓
				BS-RNase, 0.1 µg/ml	100	95	25
				BS-RNase, 1.0 µg/ml	100	50	5
				BS-RNase, 10 µg/ml	100	20	0
2	Darzynkiewicz et al., 1988 [16]	P-30 protein (Pannon)	HL-60 (Human promyelocytic leukemia)	Control	100	100	99	99	↓
				P-30, 10 µl/ml	100	90	85	70
				P-30, 20 µl/ml	100	85	66	48
3	Ardelt et al., 2007 [24]	Amphinase (Amph)	HL-60 (Human promyelocytic leukemia) U-937 (Human monocytic leukemia) Jurkat cells (T-cell leukemia)	Control			100	99	↓↓
				Amph, 1 μg/ml			80	55
				Amph, 5 μg/ml			80	40
				Amph,10 μg/ml			70	10
4	Fang et al., 2012 [34]	RNase MC2	HepG2 (human liver cancer cell)	Control	100				↓
				MC2, 15 µM	100	83	65
				MC2, 25 µM	100	75	55
				MC2, 60 µM	100	55	45
5	Joseph et al., 2020 [31]	Lp16-PSP RNase	HL-60 (Human promyelocytic leukemia)	Control		100	100		↓
				Lp16-PSP, 50 µg/ml		70	55
				Lp16-PSP, 100 µg/ml		50	25
				Lp16-PSP, 150 µg/ml		35	20
				Lp16-PSP, 200 µg/ml		25	15

*Appropriate cell densities were initially seeded for each experimental cell model. ↓ Down arrows indicate the decreasing pattern of viability

ISSN: 2396-832X